Immortalized keratinocytes derived from patients with epidermolytic ichthyosis reproduce the disease phenotype: A useful in vitro model for testing new treatments

British Journal of Dermatology

Volumn 164, Issue 2, 2011, Pages 263-272

  Chamcheu, J C ^a   Pihl Lundin, I ^a   Mouyobo, C E ^a   Gester, T ^a   Virtanen, M ^a   Moustakas, A ^b   Navsaria, H ^c   Vahlquist, A ^a   Törmä, Hans ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 PHENYLBUTYRIC ACID; ARGININE; ASPARAGINE; CALCIUM; CHAPERONE; CYTOKERATIN 10; GLYCINE; HEAT SHOCK PROTEIN 70; KERATIN; LEUCINE; LYSINE; MESSENGER RNA; TRIMETHYLAMINE OXIDE; VALINE;

ADULT; ARTICLE; CELL AGGREGATION; CELL DIFFERENTIATION; CELL GROWTH; CELL IMMORTALIZATION; CELL STRESS; CONTROLLED STUDY; CYTOLYSIS; CYTOSKELETON; EPIDERMIS; EPIDERMOLYTIC ICHTHYOSIS; GENE DELETION; GENOTYPE PHENOTYPE CORRELATION; HEAT SHOCK; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN PAPILLOMAVIRUS TYPE 16; ICHTHYOSIS; IN VITRO STUDY; IN VIVO STUDY; KERATINOCYTE; MALE; PATHOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; WILD TYPE;

ADOLESCENT; ADULT; CELL LINE; CELL TRANSFORMATION, VIRAL; EPIDERMIS; HOT TEMPERATURE; HSP70 HEAT-SHOCK PROTEINS; HUMANS; HYPERKERATOSIS, EPIDERMOLYTIC; KERATINOCYTES; KERATINS; MALE; METHYLAMINES; MODELS, BIOLOGICAL; PHENOTYPE; PHENYLBUTYRATES; STRESS, PHYSIOLOGICAL; YOUNG ADULT;

EID: 79551502364     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2010.10092.x     Document Type: Article

References (60)

1. Oji V, Tadini G, Akiyama M, et al. Revised nomenclature and classification of inherited ichthyoses: results of the First Ichthyosis Consensus Conference in Sorèze 2009. J Am Acad Dermatol 2010; 63: 607-41.
2. Covaciu C, Castori M, De Luca N, et al. Lethal autosomal recessive epidermolytic ichthyosis due to a novel donor splice-site mutation in KRT10. Br J Dermatol 2010; 162: 1384-7.
3. Terheyden P, Grimberg G, Hausser I, et al. Recessive epidermolytic hyperkeratosis caused by a previously unreported termination codon mutation in the keratin 10 gene. J Invest Dermatol 2009; 129: 2721-3.
4. Tsubota A, Akiyama M, Kanitakis J, et al. Mild recessive bullous congenital ichthyosiform erythroderma due to a previously unidentified homozygous keratin 10 nonsense mutation. J Invest Dermatol 2008; 128: 1648-52.
5. McLean WH, Eady RA, Dopping-Hepenstal PJ, et al. Mutations in the rod 1A domain of keratins 1 and 10 in bullous congenital ichthyosiform erythroderma (BCIE). J Invest Dermatol 1994; 102: 24-30.
6. DiGiovanna JJ, Robinson-Bostom L,. Ichthyosis: etiology, diagnosis, and management. Am J Clin Dermatol 2003; 4: 81-95.
7. Chipev CC, Korge BP, Markova N, et al. A leucine-proline mutation in the H1 subdomain of keratin 1 causes epidermolytic hyperkeratosis. Cell 1992; 70: 821-8.
8. Chipev CC, Yang JM, DiGiovanna JJ, et al. Preferential sites in keratin 10 that are mutated in epidermolytic hyperkeratosis. Am J Hum Genet 1994; 54: 179-90.
9. Rothnagel JA, Longley MA, Holder RA, et al. Prenatal diagnosis of epidermolytic hyperkeratosis by direct gene sequencing. J Invest Dermatol 1994; 102: 13-16.
10. Yang JM, Chipev CC, DiGiovanna JJ, et al. Mutations in the H1 and 1A domains in the keratin 1 gene in epidermolytic hyperkeratosis. J Invest Dermatol 1994; 102: 17-23.
11. Porter RM, Lane EB,. Phenotypes, genotypes and their contribution to understanding keratin function. Trends Genet 2003; 19: 278-85.
12. Cheng J, Syder AJ, Yu QC, et al. The genetic basis of epidermolytic hyperkeratosis-a disorder of differentiation-specific epidermal keratin genes. Cell 1992; 70: 811-19.
13. Rothnagel JA, Dominey AM, Dempsey LD, et al. Mutations in the rod domains of keratin-1 and keratin-10 in epidermolytic hyperkeratosis. Science 1992; 257: 1128-30.
14. Ross R, DiGiovanna JJ, Capaldi L, et al. Histopathologic characterization of epidermolytic hyperkeratosis: a systematic review of histology from the National Registry for Ichthyosis and Related Skin Disorders. J Am Acad Dermatol 2008; 59: 86-90.
15. Jones DO, Watts C, Mills C, et al. A new keratin 2e mutation in ichthyosis bullosa of Siemens. J Invest Dermatol 1997; 108: 354-6.
16. Uitto J, Richard G, McGrath JA,. Diseases of epidermal keratins and their linker proteins. Exp Cell Res 2007; 313: 1995-2009.
17. Arin MJ, Mueller FB,. Keratins and their associated skin disorders. Eur J Dermatol 2007; 17: 123-9.
18. Virtanen M, Gedde-Dahl T Jr, Mork NJ, et al. Phenotypic/genotypic correlations in patients with epidermolytic hyperkeratosis and the effects of retinoid therapy on keratin expression. Acta Derm Venereol (Stockh) 2001; 81: 163-70.
19. Bogenrieder T, Landthaler M, Stolz W,. Bullous congenital ichthyosiform erythroderma: safe and effective topical treatment with calcipotriol ointment in a child. Acta Derm Venereol (Stockh) 2003; 83: 52-4.
20. Huber M, Scaletta C, Benathan M, et al. Abnormal keratin 1 and 10 cytoskeleton in cultured keratinocytes from epidermolytic hyperkeratosis caused by keratin 10 mutations. J Invest Dermatol 1994; 102: 691-4.
21. Chamcheu JC, Virtanen M, Navsaria H, et al. Epidermolysis bullosa simplex due to KRT5 mutations: mutation-related differences in cellular fragility and the protective effects of trimethylamine N-oxide in cultured primary keratinocytes. Br J Dermatol 2010; 162: 980-9.
22. Chipev CC, Steinert PM, Woodworth CD,. Characterization of an immortalized cell line from a patient with epidermolytic hyperkeratosis. J Invest Dermatol 1996; 106: 385-90.
23. Leigh IM, Tidman MJ, Eady RA,. Epidermolysis bullosa: preliminary observations of blister formation in keratinocyte cultures. Br J Dermatol 1984; 111: 527-32.
24. Lee D, Santos D, Al-Rawi H, et al. The chemical chaperone trimethylamine N-oxide ameliorates the effects of mutant keratins in cultured cells. Br J Dermatol 2008; 159: 252-5.
25. Chamcheu JC, Pavez Loriè E, Akgul B, et al. Characterization of immortalized human epidermolysis bullosa simplex (KRT5) cell lines: trimethylamine N-oxide protects the keratin cytoskeleton against disruptive stress condition. J Dermatol Sci 2009; 53: 198-206.
26. Gerlsma SY, Stuur ER,. The effect of polyhydric and monohydric alcohols on the heat-induced reversible denaturation of lysozyme and ribonuclease. Int J Pept Protein Res 1972; 4: 377-83.
27. Gekko K, Koga S,. Increased thermal stability of collagen in the presence of sugars and polyols. J Biochem 1983; 94: 199-205.
28. Back JF, Oakenfull D, Smith MB,. Increased thermal stability of proteins in the presence of sugars and polyols. Biochemistry (Mosc) 1979; 18: 5191-6.
29. Kerns ML, DePianto D, Dinkova-Kostova AT, et al. Reprogramming of keratin biosynthesis by sulforaphane restores skin integrity in epidermolysis bullosa simplex. Proc Natl Acad Sci USA 2007; 104: 14460-5.
30. 2 histone tetramer of the core nucleosome. Protein Sci 2004; 13: 1304-16.
31. Gardian G, Browne SE, Choi DK, et al. Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. J Biol Chem 2005; 280: 556-63.
32. Placek BJ, Harrison LN, Villers BM, et al. The H2A.Z/H2B dimer is unstable compared to the dimer containing the major H2A isoform. Protein Sci 2005; 14: 514-22.
33. Villalobos AR, Renfro JL,. Trimethylamine oxide suppresses stress-induced alteration of organic anion transport in choroid plexus. J Exp Biol 2007; 210: 541-52.
34. Pruliere-Escabasse V, Planes C, Escudier E, et al. Modulation of epithelial sodium channel trafficking and function by sodium 4-phenylbutyrate in human nasal epithelial cells. J Biol Chem 2007; 282: 34048-57.
35. Löffek S, Woll S, Höhfeld J, et al. The ubiquitin ligase CHIP/STUB1 targets mutant keratins for degradation. Hum Mutat 2010; 31: 466-76.
36. Virtanen M, Smith SK, Gedde-Dahl T Jr, et al. Splice site and deletion mutations in keratin (KRT1 and KRT10) genes: unusual phenotypic alterations in Scandinavian patients with epidermolytic hyperkeratosis. J Invest Dermatol 2003; 121: 1013-20.
37. Törmä H, Geijer S, Gester T, et al. Variations in the mRNA expression of inflammatory mediators, markers of differentiation and lipid-metabolizing enzymes caused by sodium lauryl sulphate in cultured human keratinocytes. Toxicol In Vitro 2006; 20: 472-9.
38. Bui M, Liu Z,. Simple allele-discriminating PCR for cost-effective and rapid genotyping and mapping. Plant Methods 2009; 5: 1.
39. Pavez Loriè E, Chamcheu JC, Vahlquist A, et al. Both all-trans retinoic acid and cytochrome P450 (CYP26) inhibitors affect the expression of vitamin A metabolizing enzymes and retinoid biomarkers in organotypic epidermis. Arch Dermatol Res 2009; 301: 475-85.
40. Poumay Y, Coquette A,. Modelling the human epidermis in vitro: tools for basic and applied research. Arch Dermatol Res 2007; 298: 361-9.
41. Söderberg O, Gullberg M, Jarvius M, et al. Direct observation of individual endogenous protein complexes in situ by proximity ligation. Nat Methods 2006; 3: 995-1000.
42. Ortiz-Urda S, Lin Q, Green CL, et al. Injection of genetically engineered fibroblasts corrects regenerated human epidermolysis bullosa skin tissue. J Clin Invest 2003; 111: 251-5.
43. Ortiz-Urda S, Lin Q, Yant SR, et al. Sustainable correction of junctional epidermolysis bullosa via transposon-mediated nonviral gene transfer. Gene Ther 2003; 10: 1099-104.
44. Magin TM, Kaiser HW, Leitgeb S, et al. Supplementation of a mutant keratin by stable expression of desmin in cultured human EBS keratinocytes. J Cell Sci 2000; 113: 4231-9.
45. Jensen TG, Sorensen CB, Jensen UB, et al. Epidermolysis bullosa simplex keratinocytes with extended lifespan established by ectopic expression of telomerase. Exp Dermatol 2003; 12: 71-7.
46. Morley SM, D'Alessandro M, Sexton C, et al. Generation and characterization of epidermolysis bullosa simplex cell lines: scratch assays show faster migration with disruptive keratin mutations. Br J Dermatol 2003; 149: 46-58.
47. Ishida-Yamamoto A, McGrath JA, Chapman SJ, et al. Epidermolysis bullosa simplex (Dowling-Meara type) is a genetic disease characterized by an abnormal keratin-filament network involving keratins K5 and K14. J Invest Dermatol 1991; 97: 959-68.
48. Kitajima Y, Inoue S, Yaoita H,. Abnormal organization of keratin intermediate filaments in cultured keratinocytes of epidermolysis bullosa simplex. Arch Dermatol Res 1989; 281: 5-10.
49. Schuilenga-Hut PH, Vlies P, Jonkman MF, et al. Mutation analysis of the entire keratin 5 and 14 genes in patients with epidermolysis bullosa simplex and identification of novel mutations. Hum Mutat 2003; 21: 447.
50. Müller FB, Kuster W, Wodecki K, et al. Novel and recurrent mutations in keratin KRT5 and KRT14 genes in epidermolysis bullosa simplex: implications for disease phenotype and keratin filament assembly. Hum Mutat 2006; 27: 719-20.
51. Burrows JA, Willis LK, Perlmutter DH,. Chemical chaperones mediate increased secretion of mutant alpha 1-antitrypsin (alpha 1-AT) Z: a potential pharmacological strategy for prevention of liver injury and emphysema in alpha 1-AT deficiency. Proc Natl Acad Sci USA 2000; 97: 1796-801.
52. Zeitlin PL, Diener-West M, Rubenstein RC, et al. Evidence of CFTR function in cystic fibrosis after systemic administration of 4-phenylbutyrate. Mol Ther 2002; 6: 119-26.
53. Perlmutter DH,. Chemical chaperones: a pharmacological strategy for disorders of protein folding and trafficking. Pediatr Res 2002; 52: 832-6.
54. Maestri NE, Brusilow SW, Clissold DB, et al. Long-term treatment of girls with ornithine transcarbamylase deficiency. N Engl J Med 1996; 335: 855-9.
55. Dover GJ, Brusilow S, Charache S,. Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium phenylbutyrate. Blood 1994; 84: 339-43.
56. Collins AF, Pearson HA, Giardina P, et al. Oral sodium phenylbutyrate therapy in homozygous beta thalassemia: a clinical trial. Blood 1995; 85: 43-9.
57. Gondcaille C, Depreter M, Fourcade S, et al. Phenylbutyrate up-regulates the adrenoleukodystrophy-related gene as a nonclassical peroxisome proliferator. J Cell Biol 2005; 169: 93-104.
58. Andreassi C, Angelozzi C, Tiziano FD, et al. Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy. Eur J Hum Genet 2004; 12: 59-65.
59. Choo-Kang LR, Zeitlin PL,. Induction of HSP70 promotes DeltaF508 CFTR trafficking. Am J Physiol Lung Cell Mol Physiol 2001; 281: L58-68.
60. Rubenstein RC, Lyons BM,. Sodium 4-phenylbutyrate downregulates HSC70 expression by facilitating mRNA degradation. Am J Physiol Lung Cell Mol Physiol 2001; 281: L43-51.